Olanzapine-induced hypertriglyceridemia in cancer care: A silent metabolic risk
Olanzapine (Zyprexa), an atypical antipsychotic, is used off-label for managing nausea in advanced cancer patients but is linked to severe metabolic side effects, including hypertriglyceridemia. This case involves a metastatic gastric carcinoma patient with no known metabolic disorder who developed...
Saved in:
| Published in | Current problems in cancer. Case reports Vol. 17; p. 100345 |
|---|---|
| Main Authors | , , , |
| Format | Journal Article |
| Language | English |
| Published |
Elsevier Inc
01.03.2025
Elsevier |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Olanzapine (Zyprexa), an atypical antipsychotic, is used off-label for managing nausea in advanced cancer patients but is linked to severe metabolic side effects, including hypertriglyceridemia. This case involves a metastatic gastric carcinoma patient with no known metabolic disorder who developed critically elevated triglycerides (2898 mg/dL) after starting olanzapine for nausea. Her lipid levels significantly improved with medical management, allowing her to proceed for apheresis for the planned CAR-T treatment. This case underscores the need for vigilant metabolic monitoring in patients on Olanzapine (Zyprexa), even those without known risk factors, to prevent serious complications. |
|---|---|
| AbstractList | Olanzapine (Zyprexa), an atypical antipsychotic, is used off-label for managing nausea in advanced cancer patients but is linked to severe metabolic side effects, including hypertriglyceridemia. This case involves a metastatic gastric carcinoma patient with no known metabolic disorder who developed critically elevated triglycerides (2898 mg/dL) after starting olanzapine for nausea. Her lipid levels significantly improved with medical management, allowing her to proceed for apheresis for the planned CAR-T treatment. This case underscores the need for vigilant metabolic monitoring in patients on Olanzapine (Zyprexa), even those without known risk factors, to prevent serious complications. AbstractOlanzapine (Zyprexa), an atypical antipsychotic, is used off-label for managing nausea in advanced cancer patients but is linked to severe metabolic side effects, including hypertriglyceridemia. This case involves a metastatic gastric carcinoma patient with no known metabolic disorder who developed critically elevated triglycerides (2898 mg/dL) after starting olanzapine for nausea. Her lipid levels significantly improved with medical management, allowing her to proceed for apheresis for the planned CAR-T treatment. This case underscores the need for vigilant metabolic monitoring in patients on Olanzapine (Zyprexa), even those without known risk factors, to prevent serious complications. |
| ArticleNumber | 100345 |
| Author | Rumani, Imaan Kazi, Marzooka Nazim Chishti Kazi, Bilal Gaikwad, Prashant Manohar |
| Author_xml | – sequence: 1 givenname: Bilal orcidid: 0009-0000-8071-6268 surname: Kazi fullname: Kazi, Bilal email: kazibilal22@gmail.com organization: SUNACT Cancer Institute. Department of Hematology, Bone Marrow Transplantation and Cellular therapy, Tietan Medicity Hospital, Kasarvadavali, Thane, 400615, Maharashtra, India – sequence: 2 givenname: Imaan surname: Rumani fullname: Rumani, Imaan organization: SUNACT Cancer Institute. Department of Oncosurgery, Tietan Medicity Hospital, Kasarvadavali, Thane, 400615, Maharashtra, India – sequence: 3 givenname: Marzooka Nazim Chishti surname: Kazi fullname: Kazi, Marzooka Nazim Chishti organization: Department of Pharmaceutics. Y.B Chavhan College of Pharmacy. Aurangabad, India – sequence: 4 givenname: Prashant Manohar surname: Gaikwad fullname: Gaikwad, Prashant Manohar organization: Department of endocrinology, MGM Medical College and Hospital, Navi Mumbai, India |
| BookMark | eNqFkVFLHDEQx0OxULV-gr7sF9gzySbZTcWCSFsF4R5sn8NcMmtn3cseyVo4P31znhQRxKdJBv6_TH5zxA7iFJGxL4IvBBfmdFj4jfdpIblUpcMbpT-wQ2mMqY0U9uDF-RM7yXngnEsthG3VIVsuR4iPsKGINcXw4DFUf7YbTHOiu3HrMVHANUFFsfIQy72UhF-riyrTiHGu1jjDahrJV4ny_Wf2sYcx48lzPWa_f3z_dXlV3yx_Xl9e3NRetWKuWx1Ub1fWAjRGN0o2ren7leoAtAbed1LzRrRKBcV1D8F7bgVYFKBV1-q2OWbXe26YYHCbRGtIWzcBuafGlO4cpJn8iK6VwXZgDZq-0KxaiQCoQmdssWAMFFazZ_k05Zyw_88T3O0Uu8E9KXY7xW6vuKTO9yks3_xLmFz2hMVQoIR-LnPQO_lvr_J-pEgexnvcYh6mhxSLQSdclo67290SdzuUquzPmK4Azt4GvPv8P3rJrwQ |
| Cites_doi | 10.1016/S2215-0366(19)30416-X 10.1001/jamaoncol.2020.1052 10.1016/j.phrs.2015.07.022 10.2337/diacare.27.2.596 10.1097/00004714-200108000-00003 10.5694/j.1326-5377.2004.tb06443.x 10.2165/11589060-000000000-00000 |
| ContentType | Journal Article |
| Copyright | 2024 |
| Copyright_xml | – notice: 2024 |
| DBID | 6I. AAFTH AAYXX CITATION DOA |
| DOI | 10.1016/j.cpccr.2024.100345 |
| DatabaseName | ScienceDirect Open Access Titles Elsevier:ScienceDirect:Open Access CrossRef DOAJ Open Access Journals |
| DatabaseTitle | CrossRef |
| DatabaseTitleList | |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 2666-6219 |
| EndPage | 100345 |
| ExternalDocumentID | oai_doaj_org_article_72d98a96e6fd4094b1dae4d86925166a 10_1016_j_cpccr_2024_100345 S2666621924000668 1_s2_0_S2666621924000668 |
| GroupedDBID | .1- .FO 0R~ 1P~ AAEDW AALRI AAXUO AAYWO ACVFH ADCNI ADVLN AEUPX AFJKZ AFPUW AFRHN AIGII AITUG AJUYK AKBMS AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ APXCP EBS FDB GROUPED_DOAJ M41 M~E OK1 ROL Z5R AFCTW 6I. AAFTH AAYXX CITATION |
| ID | FETCH-LOGICAL-c471t-75d4f9b99aa365342376ffb48aa55a0f825031744d405fadcc091a9e1a5487573 |
| IEDL.DBID | DOA |
| ISSN | 2666-6219 |
| IngestDate | Wed Aug 27 01:30:30 EDT 2025 Tue Aug 05 12:04:53 EDT 2025 Sat Mar 29 16:11:09 EDT 2025 Thu Apr 10 14:50:33 EDT 2025 Tue Aug 26 16:31:44 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Keywords | Nausea Hypertriglyceridemia Olanzapine (Zyprexa) Dyslipidemia |
| Language | English |
| License | This is an open access article under the CC BY-NC license. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c471t-75d4f9b99aa365342376ffb48aa55a0f825031744d405fadcc091a9e1a5487573 |
| ORCID | 0009-0000-8071-6268 |
| OpenAccessLink | https://doaj.org/article/72d98a96e6fd4094b1dae4d86925166a |
| PageCount | 1 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_72d98a96e6fd4094b1dae4d86925166a crossref_primary_10_1016_j_cpccr_2024_100345 elsevier_sciencedirect_doi_10_1016_j_cpccr_2024_100345 elsevier_clinicalkeyesjournals_1_s2_0_S2666621924000668 elsevier_clinicalkey_doi_10_1016_j_cpccr_2024_100345 |
| PublicationCentury | 2000 |
| PublicationDate | 2025-03-01 |
| PublicationDateYYYYMMDD | 2025-03-01 |
| PublicationDate_xml | – month: 03 year: 2025 text: 2025-03-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationTitle | Current problems in cancer. Case reports |
| PublicationYear | 2025 |
| Publisher | Elsevier Inc Elsevier |
| Publisher_xml | – name: Elsevier Inc – name: Elsevier |
| References | Citrome, Holt, Walker, Hoffmann (bib0002) 2011; 31 Pillinger, McCutcheon, Vano (bib0008) 2020; 7 Rojo, Gaspar, Silva (bib0003) 2015; 101 Meyer (bib0004) 2001; 21 Lambert, Chapman (bib0007) 2004; 181 Navari, Pywell, Le-Rademacher (bib0001) 2020; 6 Popović, Ravanić, Janković (bib0005) 2015; 143 (bib0006) 2004; 27 Popović (10.1016/j.cpccr.2024.100345_bib0005) 2015; 143 Navari (10.1016/j.cpccr.2024.100345_bib0001) 2020; 6 Lambert (10.1016/j.cpccr.2024.100345_bib0007) 2004; 181 Meyer (10.1016/j.cpccr.2024.100345_bib0004) 2001; 21 Pillinger (10.1016/j.cpccr.2024.100345_bib0008) 2020; 7 Citrome (10.1016/j.cpccr.2024.100345_bib0002) 2011; 31 Rojo (10.1016/j.cpccr.2024.100345_bib0003) 2015; 101 (10.1016/j.cpccr.2024.100345_bib0006) 2004; 27 |
| References_xml | – volume: 143 start-page: 712 year: 2015 end-page: 718 ident: bib0005 article-title: Long-term treatment with olanzapine in hospital conditions: prevalence and predictors of the metabolic syndrome publication-title: SrpArhCelokLek – volume: 101 start-page: 74 year: 2015 end-page: 85 ident: bib0003 article-title: Metabolic syndrome and obesity among users of second generation antipsychotics: a global challenge for modern psychopharmacology publication-title: Pharmacol. Res. – volume: 31 start-page: 455 year: 2011 end-page: 482 ident: bib0002 article-title: Weight gain and changes in metabolic variables following olanzapine treatment in schizophrenia and bipolar disorder publication-title: Clin. Drug. Investig. – volume: 6 start-page: 895 year: 2020 end-page: 899 ident: bib0001 article-title: Olanzapine for the treatment of advanced cancer-related chronic nausea and/or vomiting: a randomized pilot trial publication-title: JAMA Oncol. – volume: 181 start-page: 544 year: 2004 end-page: 548 ident: bib0007 article-title: Consensus Working Group. Diabetes, psychotic disorders and antipsychotic therapy: a consensus statement publication-title: Med. J. Aust. – volume: 21 start-page: 369 year: 2001 end-page: 374 ident: bib0004 article-title: Novel antipsychotics and severe hyperlipidemia publication-title: J. Clin. Psychopharmacol. – volume: 27 start-page: 596 year: 2004 end-page: 601 ident: bib0006 article-title: Consensus development conference on antipsychotic drugs and obesity and diabetes publication-title: Diabet. Care – volume: 7 start-page: 64 year: 2020 end-page: 77 ident: bib0008 article-title: Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis publication-title: Lancet Psychiatry – volume: 7 start-page: 64 issue: 1 year: 2020 ident: 10.1016/j.cpccr.2024.100345_bib0008 article-title: Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis publication-title: Lancet Psychiatry doi: 10.1016/S2215-0366(19)30416-X – volume: 6 start-page: 895 issue: 6 year: 2020 ident: 10.1016/j.cpccr.2024.100345_bib0001 article-title: Olanzapine for the treatment of advanced cancer-related chronic nausea and/or vomiting: a randomized pilot trial publication-title: JAMA Oncol. doi: 10.1001/jamaoncol.2020.1052 – volume: 101 start-page: 74 year: 2015 ident: 10.1016/j.cpccr.2024.100345_bib0003 article-title: Metabolic syndrome and obesity among users of second generation antipsychotics: a global challenge for modern psychopharmacology publication-title: Pharmacol. Res. doi: 10.1016/j.phrs.2015.07.022 – volume: 27 start-page: 596 issue: 2 year: 2004 ident: 10.1016/j.cpccr.2024.100345_bib0006 article-title: Consensus development conference on antipsychotic drugs and obesity and diabetes publication-title: Diabet. Care doi: 10.2337/diacare.27.2.596 – volume: 21 start-page: 369 issue: 4 year: 2001 ident: 10.1016/j.cpccr.2024.100345_bib0004 article-title: Novel antipsychotics and severe hyperlipidemia publication-title: J. Clin. Psychopharmacol. doi: 10.1097/00004714-200108000-00003 – volume: 143 start-page: 712 issue: 11–12 year: 2015 ident: 10.1016/j.cpccr.2024.100345_bib0005 article-title: Long-term treatment with olanzapine in hospital conditions: prevalence and predictors of the metabolic syndrome publication-title: SrpArhCelokLek – volume: 181 start-page: 544 issue: 10 year: 2004 ident: 10.1016/j.cpccr.2024.100345_bib0007 article-title: Consensus Working Group. Diabetes, psychotic disorders and antipsychotic therapy: a consensus statement publication-title: Med. J. Aust. doi: 10.5694/j.1326-5377.2004.tb06443.x – volume: 31 start-page: 455 issue: 7 year: 2011 ident: 10.1016/j.cpccr.2024.100345_bib0002 article-title: Weight gain and changes in metabolic variables following olanzapine treatment in schizophrenia and bipolar disorder publication-title: Clin. Drug. Investig. doi: 10.2165/11589060-000000000-00000 |
| SSID | ssj0002511974 |
| Score | 2.284481 |
| Snippet | Olanzapine (Zyprexa), an atypical antipsychotic, is used off-label for managing nausea in advanced cancer patients but is linked to severe metabolic side... AbstractOlanzapine (Zyprexa), an atypical antipsychotic, is used off-label for managing nausea in advanced cancer patients but is linked to severe metabolic... |
| SourceID | doaj crossref elsevier |
| SourceType | Open Website Index Database Publisher |
| StartPage | 100345 |
| SubjectTerms | Dyslipidemia Hematology, Oncology, and Palliative Medicine Hypertriglyceridemia Nausea Olanzapine (Zyprexa) |
| Title | Olanzapine-induced hypertriglyceridemia in cancer care: A silent metabolic risk |
| URI | https://www.clinicalkey.com/#!/content/1-s2.0-S2666621924000668 https://www.clinicalkey.es/playcontent/1-s2.0-S2666621924000668 https://dx.doi.org/10.1016/j.cpccr.2024.100345 https://doaj.org/article/72d98a96e6fd4094b1dae4d86925166a |
| Volume | 17 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV27TsMwFLUQA2JBPEV5yQMjEU3iR8JWUKsKqXSASt0sx3ZEUSlVEwYWvp17naTKgOjCEilRnMe5Tu458vE1Idc6McJlFiKQWRMwnrpAZzYPwjRDttGVUuLc4dGTGE7Y45RPW0t9oSesKg9cAXcrI5smOhVO5Ba1SBZa7ZhNRAqZWQhPjSDntcQU_oMjPzzGmjJD3tBllsZgBdCIoTUgxglMrVTkK_a3MlIrywz2yV5ND2mveqwDsuUWh2RnVA-AH5HxeA5kTi9hJwA1DXGx9BWk5KoElT3_MtCf0O6u6WxBDQZ0RdHbdUd7tJhhgqHvroS4z2eGoqv8mEwG_ZeHYVCviRAYSCNlILllOeCYah0LHntTS55nLNGac93NQfDBZyoZA7B4rq0xAI5OXai9NJHxCdlefCzcKaEWELQCKII1Gq6tQeq5CNSHdNymjPEOuWngUcuq9IVqPGFvyqOpEE1Vodkh9wjh-lSsW-0PQDRVHU21KZodwpoAqGZqKPzM4EKzv-8tf2vmivqDLFSoikh11TPwESEiVJ2ebSUdItYta85RcYlNtzz7j9c9J7sRrifsPW0XZLtcfbpLIDllduX7M2xH3_0fyZ_5bQ |
| linkProvider | Directory of Open Access Journals |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Olanzapine-induced+hypertriglyceridemia+in+cancer+care%3A+A+silent+metabolic+risk&rft.jtitle=Current+problems+in+cancer.+Case+reports&rft.au=Kazi%2C+Bilal&rft.au=Rumani%2C+Imaan&rft.au=Kazi%2C+Marzooka+Nazim+Chishti&rft.au=Gaikwad%2C+Prashant+Manohar&rft.date=2025-03-01&rft.pub=Elsevier+Inc&rft.issn=2666-6219&rft.eissn=2666-6219&rft.volume=17&rft_id=info:doi/10.1016%2Fj.cpccr.2024.100345&rft.externalDocID=S2666621924000668 |
| thumbnail_m | http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F26666219%2FS2666621924X00058%2Fcov150h.gif |